Equity Long-Short, Semiconductors, Fabricated Knowledge

Douglas O'Laughlin

Equity Long-Short, Semiconductors

Fabricated Knowledge

Learn more about the world's most important manufactured product. Meaningful insight, timely analysis, and an occasional investment idea.

Equity Bottom-Up

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software.  The Company's products provide interactive 3D graphics to the mainstream personal computer market.

<ul><li>Nvidia posted earnings yesterday, and guidance was light of buy-side bogeys. I’m not going to step into the mind game of bogeys here, but there are some finer points to focus on.</li><li>NVIDIA reports Q3 EPS $0.81 ex-items vs FactSet $0.75. Reports Q3: Revenue $35.08B vs FactSet $33.17B (2 billion beat like clockwork)</li><li>Q4 Guidance: Revenue $37.5B +/- 2% vs FactSet $37.09B (a bit light). GAAP and non-GAAP gross margins are expected to be 73.0% and 73.5%, respectively, +/- 50 bps. (also light)</li></ul>

Nvidia posted earnings yesterday, and guidance was light of buy-side bogeys. I’m not going to step into the mind game of bogeys here, but there are some finer points to focus on.NVIDIA reports Q3 EPS $0.81 ex-items vs FactSet $0.75. Reports Q3: Revenue $35.08B vs FactSet $33.17B (2 billion beat like clockwork)Q4 Guidance: Revenue $37.5B +/- 2% vs FactSet $37.09B (a bit light). GAAP and non-GAAP gross margins are expected to be 73.0% and 73.5%, respectively, +/- 50 bps. (also light)

NVIDIA: Waiting on Blackwell, and the Networking Question

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Bristol Myers Squibb Co / Equity Bottom-Up

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant  rejection, and psychiatric disorders.

<ul><li>Bristol-Myers Squibb's third quarter 2024 earnings highlight a period of robust growth and strategic advancements, albeit accompanied by challenges typical of large pharmaceutical companies.</li><li>On the positive side, the company reported a noteworthy 20% revenue increase in its growth portfolio at constant currency, which now contributes to approximately half of the total revenues.</li><li>This growth is supported by products with exclusivity extending into the next decade, underscoring the company’s successful pipeline development and launch of new therapies.</li></ul>

Bristol-Myers Squibb's third quarter 2024 earnings highlight a period of robust growth and strategic advancements, albeit accompanied by challenges typical of large pharmaceutical companies.On the positive side, the company reported a noteworthy 20% revenue increase in its growth portfolio at constant currency, which now contributes to approximately half of the total revenues.This growth is supported by products with exclusivity extending into the next decade, underscoring the company’s successful pipeline development and launch of new therapies.

Bristol-Myers Squibb: Expansion into Alzheimer's Disease Psychosis Treatment As A Key Growth Catalyst! - Major Drivers

Deckers Outdoor Corporation designs and markets footwear and accessories.  The Company offers footwear for men, women and children. Deckers sells its products including accessories such as handbags, headwear, and outerwear, through domestic retailers and international distributors and directly to end-user consumers, through call centers, retail concept stores and retail outlet stores.

<ul><li>Deckers Brands experienced a robust fiscal second quarter of 2025 under the leadership of newly appointed CEO, Stefano Caroti.</li><li>The company continues to uphold its long-standing strategy while integrating four core principles to drive future growth: consumer-first mindset, brandless philosophy, innovation forward, and a globally driven approach.</li><li>These principles have significantly contributed to Deckers Brands' performance, positioning it for sustained success in the long term.</li></ul>

Deckers Brands experienced a robust fiscal second quarter of 2025 under the leadership of newly appointed CEO, Stefano Caroti.The company continues to uphold its long-standing strategy while integrating four core principles to drive future growth: consumer-first mindset, brandless philosophy, innovation forward, and a globally driven approach.These principles have significantly contributed to Deckers Brands' performance, positioning it for sustained success in the long term.

Deckers Brands' Bold Global Expansion: How Innovation & Sustainability Drive Market Leadership! - Major Drivers

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

<ul><li>AbbVie has reported noteworthy third-quarter results for 2024, outperforming expectations with strong core growth driven largely by its ex-HUMIRA platform.</li><li>The company's diversified portfolio highlighted significant achievements, with sales reaching $260 million above forecasts and demonstrating robust mid-single-digit operational sales growth.</li><li>The impressive performance of SKYRIZI and RINVOQ has been particularly pivotal, contributing to a projected combined sales of over $17 billion for the year, surpassing initial expectations by $1.3 billion.</li></ul>

AbbVie has reported noteworthy third-quarter results for 2024, outperforming expectations with strong core growth driven largely by its ex-HUMIRA platform.The company's diversified portfolio highlighted significant achievements, with sales reaching $260 million above forecasts and demonstrating robust mid-single-digit operational sales growth.The impressive performance of SKYRIZI and RINVOQ has been particularly pivotal, contributing to a projected combined sales of over $17 billion for the year, surpassing initial expectations by $1.3 billion.

AbbVie Inc.: The SKYRIZI & RINVOQ Revolution: Capturing Market Share with Game-Changing Therapies! - Major Drivers

Appian Corporation develops enterprise software solutions. The Company offers business process and cash management software. Appian serves customers worldwide.

<ul><li>Appian Corporation's third quarter of 2024 demonstrated mixed results, with notable areas of growth and some challenges.</li><li>The company's cloud subscription revenue grew by 22% year-over-year to $94.1 million, contributing to a total revenue increase of 12% to $154.1 million.</li><li>Such growth suggests strong demand for Appian's platform as organizations increasingly adopt cloud solutions.</li></ul>

Appian Corporation's third quarter of 2024 demonstrated mixed results, with notable areas of growth and some challenges.The company's cloud subscription revenue grew by 22% year-over-year to $94.1 million, contributing to a total revenue increase of 12% to $154.1 million.Such growth suggests strong demand for Appian's platform as organizations increasingly adopt cloud solutions.

Appian Corporation: Will Its Expansion in the Public Sector Be A Potential Game Changer? - Major Drivers

Equity Bottom-Up
Equity Bottom-Up Insights

NVIDIA: Waiting on Blackwell, and the Networking Question

Nvidia posted earnings yesterday, and guidance was light of buy-side bogeys. I’m not going to step into the mind game of bogeys here, but there...

Fabricated Knowledge

Bristol-Myers Squibb: Expansion into Alzheimer's Disease Psychosis Treatment As A Key Growth Catalyst! - Major Drivers

Bristol-Myers Squibb's third quarter 2024 earnings highlight a period of robust growth and strategic advancements, albeit accompanied by...

Baptista Research

Deckers Brands' Bold Global Expansion: How Innovation & Sustainability Drive Market Leadership! - Major Drivers

Deckers Brands experienced a robust fiscal second quarter of 2025 under the leadership of newly appointed CEO, Stefano Caroti. The company...

Baptista Research

Appian Corporation: Will Its Expansion in the Public Sector Be A Potential Game Changer? - Major Drivers

Appian Corporation's third quarter of 2024 demonstrated mixed results, with notable areas of growth and some challenges. The company's cloud...

Baptista Research

NVIDIA: Waiting on Blackwell, and the Networking Question

Nvidia posted earnings yesterday, and guidance was light of buy-side bogeys. I’m not going to step into the mind game of bogeys here, but there...

Fabricated Knowledge

Bristol-Myers Squibb: Expansion into Alzheimer's Disease Psychosis Treatment As A Key Growth Catalyst! - Major Drivers

Bristol-Myers Squibb's third quarter 2024 earnings highlight a period of robust growth and strategic advancements, albeit accompanied by...

Baptista Research

Deckers Brands' Bold Global Expansion: How Innovation & Sustainability Drive Market Leadership! - Major Drivers

Deckers Brands experienced a robust fiscal second quarter of 2025 under the leadership of newly appointed CEO, Stefano Caroti. The company...

Baptista Research

AbbVie Inc.: The SKYRIZI & RINVOQ Revolution: Capturing Market Share with Game-Changing Therapies! - Major Drivers

AbbVie has reported noteworthy third-quarter results for 2024, outperforming expectations with strong core growth driven largely by its ex-HUMIRA...

Baptista Research

Appian Corporation: Will Its Expansion in the Public Sector Be A Potential Game Changer? - Major Drivers

Appian Corporation's third quarter of 2024 demonstrated mixed results, with notable areas of growth and some challenges. The company's cloud...

Baptista Research